EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

How EpimAb plans to use $74M series B to accelerate its bispecific pipeline of immuno-oncology candidates

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific cancer therapies.

On Wednesday, EpimAb Biotherapeutics Inc. announced the series B round, which was co-led by Chinese

Read the full 515 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE